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S U M M A R Y
Objective: To evaluate the impact of the universal infant hepatitis B vaccination program on hepatitis B
virus (HBV) infection in Guangdong Province, China.
Methods: In 2006, a serosurvey was conducted in Guangdong Province among children aged <15 years,
14 years after the introduction of universal infant hepatitis B vaccination. The participants were selected
by stratiﬁed, multi-stage random sampling. Demographic characteristics and hepatitis B vaccination
history were collected by a questionnaire and a review of the vaccination records, and serum specimens
were tested for hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc), and
antibody to hepatitis B surface antigen (anti-HBs) by ELISA. The prevalence rate of HBV serological
markers and the rate of immunization coverage in this survey were compared with those of the 1992 and
2002 surveys.
Results: A total of 1967 children aged <15 years participated in 2006. The prevalence rate of HBsAg
decreased from 19.86% in the 1992 survey to 4.91% in the 2006 survey. The rates of three-dose and timely
birth dose coverage of hepatitis B vaccine were 92.40% and 70.84%, respectively, among children born
during the period 2002–2005. The prevalence of HBsAg was signiﬁcantly lower among fully immunized
children (1.99%) than among unvaccinated children (5.56%).
Conclusions: Guangdong Province has successfully integrated the hepatitis B vaccine into routine
immunization programs and this has had a very signiﬁcant impact on decreasing the HBsAg carrier rate
among children.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatitis B virus (HBV) infection is a serious health problem in
China.1 In 1992, the national hepatitis serological survey revealed
that the prevalence of hepatitis B surface antigen (HBsAg) was
9.75% in the population aged 1–59 years, and the rate in the 1–4
years age group was as high as the overall rate. Among the six
regions of China, the south region had the highest HBsAg
prevalence rate.2
Perinatal transmission is a major mode of HBV transmission in
China.3,4 Therefore, China has made great efforts to establish
universal infant immunization. The hepatitis B vaccine (HepB) was
recommended for routine immunization of infants by the Ministry
of Health in 1992. HepB was then fully integrated into the routine
immunization program from 2002, and infants have been
vaccinated without any charge since June 1, 2005.5,6* Corresponding author. Tel.: +86 20 89023840; fax: +86 20 84459326.
E-mail address: zhzgdcdc@163.com (H. Zheng).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.05.1027Guangdong Province is located in the south of China and is an
area with a developed economy and an open culture. This is a
highly populated province – the population was 95 million in 2006.
The 1992 serological survey revealed shocking ﬁgures for the
prevalence of HBsAg in Guangdong; this was as high as 17.85% in
the general population, and 19.86% of children aged <15 years
were found to carry HBV, making this the ﬁrst ranking province in
China.7 Following this survey, a long-term program to vaccinate
newborns against HBV was started in Guangdong; more than 1.5
million newborns beneﬁted from the HepB vaccination program
each year. In addition to the national vaccination program, a
massive HepB immunization campaign was carried out in
Guangdong Province in 2001, in which children aged <18 years
with incomplete HepB vaccination were required to obtain catch-
up injections. In 2002, another hepatitis B serological survey was
conducted in Guangdong,8 10 years after the introduction of the
universal infant HepB vaccination. Results showed that the HBsAg
prevalence rate among children had decreased dramatically, from
19.86% to 8.56%.
The latest provincial hepatitis B serological survey was
conducted in 2006, 4 years after the routine immunizationses. Published by Elsevier Ltd. All rights reserved.
J. Xiao et al. / International Journal of Infectious Diseases 16 (2012) e692–e696 e693program. This survey aimed to determine the prevalence rates of
HBV markers and HepB vaccination coverage among children born
after universal hepatitis B vaccination was introduced, and to
compare the results with those of the 1992 and 2002 surveys.
2. Materials and methods
2.1. Study population and sample method
In September 2006, a cross-sectional serological survey was
conducted in Guangdong Province, China. The target population
was children aged <15 years at each of six national disease
surveillance points (DSP), which were selected by the Chinese
Center for Disease Control and Prevention (CDC) to be representa-
tive of the population of Guangdong Province. The six DSP could be
divided into an urban group (Guangzhou, Shanwei, Yunfu) and a
rural group (Shaoguan, Zhaoqing, Meizhou) (Figure 1). The subjects
were selected by stratiﬁed, multi-stage random sampling in these
six DSP. Three sub-districts in each urban district, two towns in
each rural county, and one resident commission (village) in each
sub-district (town) were selected randomly. In the selected
resident commission (village), all children aged 1–4 years were
interviewed and participants aged 5–14 years were chosen by
systematic sampling.
2.2. Investigation
A house-to-house investigation was completed by trained staff
using a standard questionnaire. Written informed consent was
provided by the parents of all children who participated in this
survey. The child’s immunization status was recorded from their
home immunization certiﬁcate, or if not available, the immuniza-
tion information was recorded from the parent’s description.
Otherwise, the immunization information was recorded as
unvaccinated or unknown. Full vaccination was deﬁned as receipt
of three doses of HepB within 12 months, as documented by any
immunization record. Timely birth-dose coverage was deﬁned as
receipt of the ﬁrst dose of HepB within 24 h after birth.Figure 1. Geographic distribution of districts2.3. Specimen collection and laboratory testing
The laboratory testing method was in accordance with a
previous report.5 Blood samples were obtained from each study
participant (4 ml for children aged 2 years and 2 ml for children
aged <2 years). Serum was initially separated in the local
laboratories and was subsequently transported to provincial
laboratories. All serum specimens were sent to the National
Hepatitis Laboratory for testing. HBsAg, antibody to hepatitis B
surface antigen (anti-HBs), and antibody to hepatitis B core antigen
(anti-HBc) were detected using an ELISA kit.
2.4. Data analysis
All data were double-inputted using Epi Data 3.1 software and
were checked for consistency and accuracy. The data were
analyzed using SPSS 16.0 software (SPSS, Chicago, IL, USA). The
rate was weighted by age, gender, and district on the basis of the
data of the 2000 national census of Guangdong Province.
3. Results
3.1. Characteristics of the study population
Overall, 1967 children aged <15 years participated in 2006. A
total of 763 were aged 1–4 years and 1204 were aged 5–14 years.
The sex and district distributions were as follows: 1078 males
(54.8%) and 889 females (45.2%); 985 (50.1%) from urban areas and
982 (49.9%) from rural areas.
3.2. Distribution of HBV serological markers by age
In the 2006 serological survey, the weighted prevalence rates of
HBsAg, anti-HBs, anti-HBc, and HBV infection were 4.91%, 61.87%,
9.35%, and 18.00%, respectively, among children aged <15 years
(Table 1). The HBsAg prevalence decreased steadily with decreas-
ing age and the prevalence rate was lowest in 1-year-old children
(0.64%) (Figure 2). The anti-HBs prevalence rate in 1-year-olds was sampled in Guangdong Province, China.
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J. Xiao et al. / International Journal of Infectious Diseases 16 (2012) e692–e696e694signiﬁcantly higher than that for the other age groups. The highest
prevalence rates of anti-HBc and HBV infection were observed in
children aged 10–14 years.
In comparison with the 1992 and 2002 surveys, which
investigated 1032 and 1963 children aged <15 years, respectively,
the HBsAg prevalence rate among children decreased dramatically
from 19.86% to 4.91%, and the HBV infection rate decreased from
71.41% to 18.00%, while the anti-HBs rate increased from 37.21% to
61.87%. These trends were observed in all age groups (Figure 2).
3.3. Distribution of HBV serological markers by sex and district
HBsAg prevalence was signiﬁcantly higher for males than
females (5.19% vs. 4.05%, p < 0.05) and this phenomenon was also
observed in both the 1992 and 2002 surveys (Table 1). The HBsAg
prevalence among persons living in rural areas was higher than
among those living in urban areas (7.43% vs. 1.93%, p < 0.01) and
the prevalence of anti-HBs was higher in urban than in rural areas
(65.99% vs. 57.74%, p < 0.05). Similarly, these phenomena were
also observed in both the 1992 and 2002 surveys (Table 1).
3.4. Immunization coverage of hepatitis B vaccine for
children aged <5 years
The survey found that immunization records were not well kept
during the 1990s; the HepB vaccination history for those with no
written records was obtained by interviewing the child’s parents,
so the immunization history in a large portion of children aged >10
years was undeﬁned. Thus, the analysis of immunization coverage
was based only on children aged <5 years.
For children born during the period 2002–2005, the rates of
weighted three-dose and timely birth dose coverage of HepB were
92.40% and 70.84%, respectively. The coverage rate increased
steadily with decreasing age. In addition, although there was no
signiﬁcant difference in the rates of three-dose coverage between
urban and rural areas, the prevalence of timely birth dose coverage
was higher in urban than in rural areas (80.51% vs. 58.80%, p <
0.05). Compared to the same age group in the 2002 survey, the
rates of three-dose and timely birth dose coverage of HepB
increased from 86.10% to 92.40%, and from 65.71% to 70.84%,
respectively (Table 2).
3.5. Prevalence of HBsAg and other HBV markers and
immunization history
Different histories of hepatitis B immunization led to obvious
differences in the distributions of HBV prevalence. The prevalence
of HBsAg was signiﬁcantly lower among children who had been
fully vaccinated than among unvaccinated children and among
those with unknown immunization status. The prevalence of
HBsAg was 1.99% among children born during 2002–2005 who
received the full three-dose immunization series, while among
children who had not been immunized, the prevalence of HBsAg
was 5.56%. The prevalence of anti-HBs was higher among fully
immunized children (72.65%) than among unvaccinated children
(27.78%). The prevalence of anti-HBc was signiﬁcantly lower
among fully immunized children (3.28%) than among unvaccinat-
ed children (5.56%). A comparison between the 2002 and 2006
survey results showed that they were in accordance with each
other (Table 3).
4. Discussion
Endemic HBV infection is a serious health problem in China,
especially in Guangdong Province.7 Vaccination is considered the
most cost-effective way to control hepatitis B, and immunization
Figure 2. Comparison of the age-speciﬁc prevalence rate of (A) HBsAg, (B) anti-HBs, (C) anti-HBc, and (D) HBV infection among children aged 1–14 years in 1992, 2002, and
2006 in Guangdong Province.
Table 3
The distributions of HBV serological markers by different history of hepatitis B immunization in children aged 1–4 years in 2002 and 2006
Number
investigated
HBsAg prevalence
% (95% CI)
Anti-HBs prevalence
% (95% CI)
Anti-HBc prevalence
% (95% CI)
2002
Vaccinated 461 3.90 (2.14–5.67) 78.31 (74.55–82.07) 9.33 (6.67–11.98)
Unvaccinated 50 12.00 (2.99–21.01) 50.00 (48.55–75.45) 24.00 (12.16–35.84)
Unknown 14 14.29 (2.00–43.00) 57.14 (31.22–83.07) 14.29 (2.00–43.00)
2006
Vaccinated 702 1.99 (0.96–3.03) 72.65 (69.35–75.95) 3.28 (1.96–4.59)
Unvaccinated 18 5.56 (0–16.14) 27.78 (7.09–48.47) 5.56 (0–16.14)
Unknown 43 4.65 (0–10.95) 55.81 (40.97–70.66) 4.65 (2.12–4.69)
HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; anti-HBs, antibody to hepatitis B surface antigen; anti-HBc, antibody to hepatitis B core antigen; 95% CI, 95%
conﬁdence interval.
Table 2
Immunization coverage of hepatitis B vaccine for children aged 1–4 years in 2002 and 2006
2002 2006
Age, years Number
investigated
Three dose coverage
% (95% CI)
Timely birth dose
coverage % (95% CI)
Number
investigated
Three dose coverage
% (95% CI)
Timely birth
dose coverage
% (95% CI)
1 131 90.84 (85.90–95.78) 77.31 (70.14–84.48) 158 94.30 (90.68–97.92) 80.18 (70.64–83.72)
2 112 86.77 (80.50–93.04) 68.69 (60.10–77.28) 194 91.81 (87.95–95.67) 73.49 (67.28–79.70)
3 145 81.38 (75.04–87.72) 62.10 (54.20–69.99) 221 90.50 (86.63–94.37) 61.32 (54.90–67.74)
4 137 78.42 (71.53–85.31) 54.55 (46.21–62.88) 190 89.47 (85.11–93.83) 58.38 (51.37–65.39)
Urban/rural
Urban 130 96.42 (92.84–99.46) 80.00 (73.12–86.88) 382 92.67 (90.06–95.28) 80.51 (75.46–83.56)
Rural 395 82.78 (79.06–86.50) 60.24 (55.42–65.07) 381 92.02 (89.30–94.74) 58.80 (53.86–63.74)
Total 525 86.10 (83.14–89.06) 65.71 (61.65–69.77) 763 92.40 (90.52–94.28) 70.84 (66.58–73.10)
95% CI, 95% conﬁdence interval.
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Since 1992, Guangdong has made strong efforts to establish
universal infant immunization. Based on comparative studies of
three serosurveys, the most dramatic ﬁnding is a signiﬁcant
decline in the prevalence of HBsAg among children born after HepB
was recommended for routine infant immunization in 1992, and
especially for children born after HepB was fully integrated into
routine infant immunization in 2002. Conversely, the prevalence of
anti-HBs for the population aged <15 years has increased from
37.21% in 1992 before HepB was recommended, to 61.87% in 2006.
The present study showed that children aged 1 year had a
signiﬁcantly lower prevalence of HBsAg and higher prevalence of
anti-HBs than older children. This could potentially be explained
by higher HepB coverage among newborns.
The successful introduction of HepB into the national immuni-
zation program has had a great impact on the prevalence of HBsAg
among children. The results of the 2002 and 2006 surveys both
afﬁrm that universal vaccination of infants has contributed directly
to the reduction in the prevalence of HBsAg. The prevalence of
HBsAg was signiﬁcantly lower and the prevalence of anti-HBs
signiﬁcantly higher among children who had been fully vaccinated
than among unvaccinated children and among those with an
unknown immunization status. These data are consistent with
those of many studies in China,8,10–12 which have shown the
prevalence of HBsAg to have declined signiﬁcantly since the
introduction of the hepatitis B vaccination programs. The decline in
HBsAg among children in China can be attributed primarily to the
impact of hepatitis B vaccination.
Though there has been a decrease in the prevalence of HBV
among young children in Guangdong Province similar to that
reported in Shandong Province of China,12 the HBsAg prevalence
has remained at a relatively high level in Guangdong, and this
phenomenon is more serious in rural areas. Lots of data have
revealed that the timely administration of the birth dose within
24 h after birth is highly effective for the prevention of hepatitis B
among children born to highly infectious HBsAg-positive mothers,
and it is strongly recommended that hepatitis B vaccination
programs provide the birth dose in a timely manner.10,13–15 The
2006 survey showed that immunization coverage remained very
low in rural areas and that children born in rural areas were more
vulnerable to not receiving a timely birth dose or full immuniza-
tion. Because a high proportion of women of childbearing age
remain HBsAg- and hepatitis B e antigen (HBeAg)-positive, to
achieve additional gains in reducing the hepatitis B risk among
children, the authorities must continue to improve immunization,
in particular the timely administration of birth doses, for these
high-risk groups.
This study has several limitations. First, the analysis of
immunization coverage was based only on children aged <5
years, so we were unable to determine the relationship between
the prevalence of HBsAg and immunization history among
children aged 5–14 years. Second, the target population was
children who had lived in a village for 6 months, and some ﬂoating
(migrant) children and children who had been born outside of the
birth control plan were excluded from the study. Therefore, there
may be some bias in this study, such as overestimating
immunization coverage or underestimating HBsAg prevalence.
In the past 4 years, from 2007 to 2010, our monitoring data
show that the immunization coverage rate has increased and that
the prevalence of HBsAg has decreased steadily among children in
Guangdong Province. A hepatitis B serological sampling survey
was conducted in the province in 2010. The results showed that theprevalence of HBsAg was 1.70% (9/529) among children aged <15
years and 0.60% (2/333) among children aged <7 years, which
indicates the achievement of the national goal of a 1% HBsAg
prevalence among children by 2010 and of the World Health
Organization Regional Ofﬁce for the Western Paciﬁc hepatitis B
reduction goal. However, larger scale studies are needed to conﬁrm
these results.
In conclusion, Guangdong Province has successfully integrated
HepB into routine immunization programs and this has had a very
signiﬁcant impact on decreasing the HBsAg carrier rate among
children born after 1992. However, in rural areas, the HBsAg
prevalence remains at a relatively high level among children, and
the immunization coverage rate is still not high. To further reduce
the prevalence of HBsAg, free vaccination of infants should be
maintained and all infants should be targeted for a timely birth
dose. In addition, Guangdong should focus on expanding coverage
to all children aged <15 years.
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